FULC Fulcrum Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why FULC matters now
Fulcrum Therapeutics, Inc. (FULC) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.59 with -3.75% on the session and $194.3M in market capitalization; recent performance reads 1-month -37.39% and YTD -67.29%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-18.9M, and EPS of $-0.25. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -31.9%.
The latest indexable market news headline is "Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $4.00; recent insider activity includes Lehrer-Graiwer Joshua filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.85
P/S
0.00
EV/EBITDA
-2.08
DCF Value
$3.01
FCF Yield
-31.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-27.8%
ROA
-21.9%
ROIC
-25.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-18.9M | $-0.25 |
| Q4 2025 | $0.00 | $-20.3M | $-0.31 |
| FY 2025 | $0.00 | $-74.9M | $-1.18 |
| Q3 2025 | $0.00 | $-19.6M | $-0.31 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$3.60
Target (Median)
$4.00
Target Range
$3.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.92
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.